Reshape Lifesciences INC 8-K filings
ReShape Lifesciences is set to merge with Vyome Therapeutics and sell assets to Biorad Medisys, pending shareholder approval and regulatory filings.
ReShape Lifesciences has received a notice from Nasdaq for failing to maintain the minimum required stockholders' equity of $2.5 million, putting its listing status at risk.
ReShape Lifesciences announced its third quarter 2024 financial results, highlighting revenue growth and a strategic merger and asset sale.
ReShape Lifesciences has entered into a securities purchase agreement for a $833,333 senior secured convertible note with an institutional investor.
ReShape Lifesciences has enacted a 1-for-58 reverse stock split, effective for trading on September 23, 2024.
ReShape Lifesciences has entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys, while also reporting a significant reduction in operating expenses.
ReShape Lifesciences will combine with Vyome Therapeutics in an all-stock merger, while simultaneously selling its assets to Biorad Medisys for $5.16 million.
ReShape Lifesciences announced its first quarter 2024 financial results, showcasing a significant reduction in operating expenses and the ongoing commercial launch of its Lap-Band 2.0 FLEX.
ReShape Lifesciences has been granted a second extension until October 7, 2024, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
ReShape Lifesciences Inc. has replaced its independent auditor, RSM US LLP, with Haskell & White LLP, effective April 8, 2024.
ReShape Lifesciences reported a decrease in 2023 revenue due to GLP-1 drug competition but is implementing a significant cost reduction plan and launching its next-generation Lap-Band 2.0 FLEX.
ReShape Lifesciences Inc. held its annual meeting on February 23, 2024, where stockholders approved the election of directors, a potential reverse stock split, and other key proposals.
ReShape Lifesciences received a delisting notice from Nasdaq for not holding an annual shareholder meeting and subsequently amended its bylaws to reduce the quorum requirement for shareholder meetings.